Laurus Labs Ltd Q4 FY27 Earnings Call Analysis

- FY’27 and FY’28 expected growth: - Significant growth anticipated in API and formulations, especially FY’28 due to new capacities and generic API validation. - ARV segment expected stable in the Rs. 2,500 – 3,000 crore range. - Gross margins: - Targeting sustained gross margin of around 60% in coming quarters and FY’27. - CDMO business: - Delivered over 50% growth in 9 months FY’26; expected to sustain growth with new commercial molecules. - Growth is lumpy quarter-on-quarter but strong on a yearly basis. - Profitability: - EBITDA margin around 26%-27% anticipated. - Profit after tax showed strong 388% growth in 9 months FY’26. - Asset turnover aimed to improve from current 0.9 to 1.1 in medium term. - Operating cash flow conversion expected to improve sustainably going forward, aided by changing business mix and customer advances. Overall, Laurus Labs expects strong and sustainable top-line growth, margin stability, and improved profitability over the next 2-3 years.

- The transcript does not provide explicit details on the current or expected order book or pending orders for Laurus Labs Limited. - However, it's mentioned that the CDMO business has strong recurring business from existing long-term customer relationships and a healthy pipeline with a well-balanced mix of big pharma, mid-, and small-sized biotechs. - The company supplies multiple commercial molecules and is investing in capacity expansion, including peptides and advanced technologies. - For human health CDMO, several programs with partners are ongoing with commercial supplies. - Crop science CDMO products have been commercialized with meaningful supply expected in 1-2 years. - Discussions with large pharma on late-stage molecules continue but no specific order details were disclosed due to confidentiality. - The generic division shows growing volumes supported by recently launched products in developed markets. No specific order book value or exact pending order details were disclosed.